Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
August 03, 2023 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2023 financial...
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
August 01, 2023 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the Phase 2b...
Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023
June 16, 2023 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., June 16, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023
June 15, 2023 07:30 ET
|
Altimmune, Inc
Presentation Selected for Best of EASL Summary Slides Altimmune to Host a NASH KOL and Investor Reception on June 22, 2023 GAITHERSBURG, Md., June 15, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc....
Altimmune to Participate at Two Upcoming Investor Conferences
May 31, 2023 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
May 11, 2023 07:00 ET
|
Altimmune, Inc
Initiation of the IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) expected mid-2023 Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 ...
Altimmune to Participate at Two Upcoming Investor Conferences
May 08, 2023 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 08, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
May 04, 2023 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2023 financial...
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B
April 11, 2023 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., April 11, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the Company), today announced that it has completed enrollment in its...
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
March 27, 2023 16:05 ET
|
Altimmune, Inc
GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to...